Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
MCK · NYSE · United States · Wholesale-Drugs, Proprietaries & Druggists' Sundries
In shortMCKESSON CORP is profitable.
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 1.5% | 22/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 1.2% | 25/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 117.3% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 0.85× | 4/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.39× | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 25.15× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 0.58 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 1.4% | 26/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.20× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 4.1% | 96/100 |
| Operating margin volatility | 0.3% | 100/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 13.4% | 91/100 |
|---|---|---|
| EPS growth, 3-year average | 15.3% | 100/100 |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 263,966 | 276,711 | 308,951 | 359,051 | 403,430 |
| Cost of revenue | 250,836 | 264,353 | 296,123 | 345,728 | 388,880 |
| Gross profit | 13,130 | 12,358 | 12,828 | 13,323 | 14,550 |
| Selling, general & admin | 10,537 | 7,776 | 8,657 | 8,507 | 8,096 |
| Operating income | 2,038 | 4,381 | 3,909 | 4,422 | 6,212 |
| Interest expense | 178 | 248 | 252 | 265 | 247 |
| Pre-tax income | 1,928 | 4,630 | 3,789 | 4,359 | 6,201 |
| Income tax | 636 | 905 | 629 | 878 | 1,102 |
| Net income | 1,114 | 3,560 | 3,002 | 3,295 | 4,762 |
| Diluted EPS | $7.23 | $25.03 | $22.39 | $25.72 | $38.38 |
| Diluted shares (millions) | 154 | 142 | 134 | 128 | 124 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
0.58 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026